Oncotelic Therapeutics Inc
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, w… Read more
Oncotelic Therapeutics Inc (OTLC) - Net Assets
Latest net assets as of September 2025: $8.08 Million USD
Based on the latest financial reports, Oncotelic Therapeutics Inc (OTLC) has net assets worth $8.08 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($28.16 Million) and total liabilities ($20.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.08 Million |
| % of Total Assets | 28.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | -40.09% |
| 10-Year Change | N/A |
| Growth Volatility | 67.83 |
Oncotelic Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Oncotelic Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncotelic Therapeutics Inc (2017–2024)
The table below shows the annual net assets of Oncotelic Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.48 Million | -35.60% |
| 2023-12-31 | $11.61 Million | -39.50% |
| 2022-12-31 | $19.19 Million | +135.26% |
| 2021-12-31 | $8.16 Million | -34.63% |
| 2020-12-31 | $12.48 Million | -26.16% |
| 2019-12-31 | $16.90 Million | +4768.97% |
| 2018-12-31 | $-362.00K | +24.11% |
| 2017-12-31 | $-477.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncotelic Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3326266800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $46.29 Million | 561.01% |
| Total Equity | $8.25 Million | 100.00% |
Oncotelic Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Oncotelic Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KPM TECH Co. Ltd
KQ:042040
|
$13.59 Million |
|
Precise Biometrics AB (publ)
PINK:PRBCF
|
$13.59 Million |
|
Trimitra Prawara Goldland Tbk Pt
JK:ATAP
|
$13.60 Million |
|
The Ruby Mills Limited
NSE:RUBYMILLS
|
$13.60 Million |
|
Korea SE Corp
KQ:101670
|
$13.58 Million |
|
S.A.L. Steel Limited
NSE:SALSTEEL
|
$13.58 Million |
|
Champion Technology Holdings Ltd
PINK:CPIHF
|
$13.56 Million |
|
FM Global Logistics Holdings Bhd
KLSE:7210
|
$13.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncotelic Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,130,129 to 8,251,631, a change of -3,878,498 (-32.0%).
- Net loss of 4,523,932 reduced equity.
- Other factors increased equity by 645,434.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.52 Million | -54.82% |
| Other Changes | $645.43K | +7.82% |
| Total Change | $- | -31.97% |
Book Value vs Market Value Analysis
This analysis compares Oncotelic Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.02 | $0.06 | x |
| 2018-12-31 | $-0.01 | $0.06 | x |
| 2019-12-31 | $0.20 | $0.06 | x |
| 2020-12-31 | $0.13 | $0.06 | x |
| 2021-12-31 | $0.02 | $0.06 | x |
| 2022-12-31 | $0.05 | $0.06 | x |
| 2023-12-31 | $0.03 | $0.06 | x |
| 2024-12-31 | $0.02 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncotelic Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.23x
- Recent ROE (-54.82%) is below the historical average (-41.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.76 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.70 Million |
| 2019 | -39.27% | -1947.46% | 0.01x | 1.40x | $-8.33 Million |
| 2020 | -80.72% | -545.86% | 0.07x | 2.01x | $-10.68 Million |
| 2021 | -118.04% | 0.00% | 0.00x | 2.97x | $-10.19 Million |
| 2022 | 26.25% | 0.00% | 0.00x | 1.86x | $3.15 Million |
| 2023 | -65.15% | -11290.13% | 0.00x | 2.47x | $-9.12 Million |
| 2024 | -54.82% | 0.00% | 0.00x | 3.23x | $-5.35 Million |
Industry Comparison
This section compares Oncotelic Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncotelic Therapeutics Inc (OTLC) | $8.08 Million | 0.00% | 2.49x | $13.58 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |